How have mRNA technology advancements transformed the vaccine development landscape for viral diseases like influenza and RSV beyond COVID-19?
DOI:
https://doi.org/10.58445/rars.2320Keywords:
mRNA Technology, COVID-19, Influenza, RSVAbstract
The COVID-19 pandemic has exposed the vulnerability of global public health systems to emerging viral threats, disrupting lives and economies worldwide. By January 2025, SARS-CoV-2 caused over 700 million infections and millions of deaths globally, prompting an urgent search for rapid and effective vaccines. Traditional vaccine platforms often require years of development and manufacturing, a timeline incompatible with the immediate demands of a global pandemic. This challenge catalyzed the rise of messenger RNA (mRNA) vaccine technology, which revolutionized vaccine development by significantly reducing production timelines and enhancing adaptability.
mRNA vaccines represent a paradigm shift in vaccinology. Unlike conventional approaches, these vaccines use synthetic mRNA to instruct host cells to produce antigenic proteins, eliciting immune responses. The success of mRNA-based COVID-19 vaccines, such as those developed by Pfizer-BioNTech and Moderna, highlight their immense potential. Their rapid development, high efficacy, and scalable production provided a blueprint for combating future pandemics and overcoming long-standing challenges in vaccine development for diseases like influenza and respiratory syncytial virus (RSV).
Beyond COVID-19, the applicability of mRNA technology extends to other infectious diseases, including those that have eluded traditional vaccine strategies. Influenza, RSV, and even emerging zoonotic viruses could benefit from the modular and adaptable nature of mRNA platforms. The capability to rapidly design and produce vaccines based on genetic sequencing alone positions mRNA technology as a cornerstone of future pandemic preparedness and routine immunization programs.
This paper examines how advancements in mRNA technology have expanded its transformative influence beyond COVID-19. It first provides an overview of mRNA technology’s foundational principles and historical development. Next, it explores the role of mRNA technology in the creation of COVID-19 vaccines, emphasizing their adaptability and effectiveness. Finally, the discussion pivots to the broader application of mRNA vaccines in combating other viral diseases, emphasizing ongoing research and future directions.
References
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. et al (2018). mRNA vaccines — a new era in Vaccinology. Nature Reviews Drug Discovery, 17(4), 261–279. https://doi.org/10.1038/nrd.2017.243
Corbett, K.S., Edwards, D.K., Leist, S.R. et al (2020). SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571. https://doi.org/10.1038/s41586-020-2622-0
Polack, F. P., et al (2020). Safety and efficacy of the BNT162B2 mrna covid-19 vaccine. New England Journal of Medicine, 383(27), 1576–1578. https://doi.org/10.1056/NEJMoa2034577
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. et al (2008). Incorporation of pseudouridine into mrna yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy, 16(11), 1833–1840. https://doi.org/10.1038/mt.2008.200
U.S. National Library of Medicine. (n.d.). What are mrna vaccines and how do they work?: Medlineplus Genetics. MedlinePlus. https://medlineplus.gov/genetics/understanding/therapy/mrnavaccines/
World Health Organization. (n.d.). Covid-19 cases | WHO COVID-19 Dashboard. World Health Organization. https://data.who.int/dashboards/covid19/cases
Barton, C. (2024, August 7). MRNA technologies: Looking beyond covid vaccines. pharmaphorum. https://pharmaphorum.com/rd/mrna-technologies-looking-beyond-covid-vaccines
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019). Advances in mrna vaccines for infectious diseases. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.00594
Stobbe, M., & Neergaard, L. (2024, May 31). Scientists are testing mrna vaccines to protect cows and people against Bird Flu. AP News. https://apnews.com/article/bird-flu-mrna-vaccine-ab3cf2df5ef7dca8f56d279205a97ff7
Laise, E. (2024, September 4). Moderna’s experimental mpox vaccine reduces severity of disease, early study finds. MarketWatch. https://www.marketwatch.com/story/modernas-experimental-mpox-vaccine-reduces-severity-of-disease-early-study-finds-36ff0b7a
Mole, B. (2024, July 4). US government awards moderna $176 million for mrna bird flu vaccine. Wired. https://www.wired.com/story/moderna-mrna-vaccine-bird-flu-h5n1/
Howard, S., & Krishna, G. (2024, September 12). Public health in global south faces vaccine cold storage challenge. Financial Times. https://www.ft.com/content/ad0b0e49-9813-4f10-92fa-d2317dd88c86
U.S. National Library of Medicine. (n.d.). PubMed. National Center for Biotechnology Information. https://pubmed.ncbi.nlm.nih.gov/
Lipsitch, M., & Kahn, R. (2021). Interpreting vaccine efficacy trial results for infection and transmission. MedRXiv. https://doi.org/10.1101/2021.02.25.21252415
Lee, J., Woodruff, M. C., Kim, E. H., & Nam, J.-H. (2023). Knife’s Edge: Balancing immunogenicity and reactogenicity in mrna vaccines. Experimental & Molecular Medicine, 55(7), 1305–1313. https://doi.org/10.1038/s12276-023-00999-x
Explore scientific, technical, and medical research on ScienceDirect. ScienceDirect.com | Science, health and medical journals, full text articles and books. (n.d.). https://www.sciencedirect.com/
Miles, T. (2019, May 21). Vaccine doubts spread like disease, must be taken offline: Vaccine chief . Reuters. https://www.reuters.com/article/us-health-vaccines/vaccine-doubts-spread-like-disease-must-be-taken-offline-vaccine-chief-idUSKCN1SR1SV/
Kumar, A., Blum, J., Thanh Le, T., Havelange, N., Magini, D., & Yoon, I.-K. (2022). The mrna vaccine development landscape for infectious diseases. Nature Reviews Drug Discovery, 21(5), 333–334. https://doi.org/10.1038/d41573-022-00035-z
World Health Organization. (2021). Vaccine equity. World Health Organization. https://www.who.int/campaigns/vaccine-equity?utm_source
Centers for Disease Control and Prevention. (2024, December 28). Weekly US Influenza Surveillance Report: Key Updates for Week 52, ending December 28, 2024. Centers for Disease Control and Prevention. https://www.cdc.gov/fluview/surveillance/2024-week-52.html
Moderna announces interim phase 3 safety and immunogenicity results for mrna-1010, a seasonal influenza vaccine candidate. Moderna. (2023, February 16). https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Interim-Phase-3-Safety-and-Immunogenicity-Results-for-mRNA-1010-a-Seasonal-Influenza-Vaccine-Candidate/default.aspx
Krammer, F., & Palese, P. (2015). Advances in the development of influenza virus vaccines. Nature Reviews Drug Discovery, 14(3), 167–182. https://doi.org/10.1038/nrd4529
Roberts, J. N., Graham, B. S., Karron, R. A., Munoz, F. M., Falsey, A. R., Anderson, L. J., Marshall, V., Kim, S., & Beeler, J. A. (2016). Challenges and opportunities in RSV Vaccine Development: Meeting Report from FDA/NIH Workshop. Vaccine, 34(41), 4843–4849. https://doi.org/10.1016/j.vaccine.2016.07.057
Topalidou, X., Kalergis, A. M., & Papazisis, G. (2023). Respiratory syncytial virus vaccines: A review of the candidates and the approved vaccines. Pathogens, 12(10), 1259. https://doi.org/10.3390/pathogens12101259
Sullender, W. (2000). Respiratory syncytial virus genetic and antigenic diversity. Clinical Microbiology Reviews, 13(1), 1–15. https://doi.org/10.1128/cmr.13.1.1-15.2000
Espeseth, A. S., Cejas, P. J., Citron, M. P., Wang, D., DiStefano, D. J., Callahan, C., Donnell, G. O., Galli, J. D., Swoyer, R., Touch, S., Wen, Z., Antonello, J., Zhang, L., Flynn, J. A., Cox, K. S., Freed, D. C., Vora, K. A., Bahl, K., Latham, A. H., … Bett, A. J. (2020). Modified mrna/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. Npj Vaccines, 5(1). https://doi.org/10.1038/s41541-020-0163-z
Barouch, D. H. (2008). Challenges in the development of an HIV-1 vaccine. Nature, 455(7213), 613–619. https://doi.org/10.1038/nature07352
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A., Flach, B., Doria-Rose, N. A., Corbett, K. S., Morabito, K. M., O’Dell, S., Schmidt, S. D., Swanson, P. A., … Beigel, J. H. (2020). An mrna vaccine against SARS-COV-2 — preliminary report. New England Journal of Medicine, 383(20), 1920–1931. https://doi.org/10.1056/nejmoa2022483
Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O., & De Gregorio, E. (2016). Reverse Vaccinology 2.0: Human immunology instructs vaccine antigen design. Journal of Experimental Medicine, 213(4), 469–481. https://doi.org/10.1084/jem.20151960
Moderna. (2023, October 4). Moderna announces positive phase 1/2 data from mRNA-1083, the company’s combination vaccine against influenza and covid-19. https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Positive-Phase-12-Data-from-mRNA-1083-the-Companys-Combination-Vaccine-Against-Influenza-and-COVID-19/default.aspx
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study. Pfizer. (2021, April 1). https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious
World Health Organization. (2021, June 21). The mRNA vaccine technology transfer hub. World Health Organization. https://www.who.int/initiatives/the-mrna-vaccine-technology-transfer-hub
Sahin, U., Karikó, K., & Türeci, Ö. (2014). mRNA-based therapeutics—developing a new class of drugs. Nature Reviews Drug Discovery, 13(10), 759–780. https://doi.org/10.1038/nrd4278
Kwon, J., Lee, Y., Lee, H., & Shin, S. (2022). Advances in mRNA therapeutics: Systematic review of the manufacturing processes and challenges. Journal of Pharmaceutical Investigation, 52(1), 1–15. https://doi.org/10.1007/s40005-021-00539-0
Liu, M. A., VanBlargan, L. A., Rothlauf, P. W., & Bloom, J. D. (2023). Rapid adaptation of mRNA vaccines for emerging viral threats. Cell Reports Medicine, 4(3), 100926. https://doi.org/10.1016/j.xcrm.2023.100926
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021). mRNA vaccines for infectious diseases: Principles, delivery and clinical translation. Nature Reviews Drug Discovery, 20(11), 817–838. https://doi.org/10.1038/s41573-021-00283-5
Cox, R. J., & Peacock, S. J. (2021). mRNA vaccines for SARS-CoV-2: The tipping point for vaccines and the future. NPJ Vaccines, 6, 1-8. https://doi.org/10.1038/s41541-021-00356-x
Moderna. (2023a, January 17). Moderna announces mRNA-1345, an investigational respiratory syncytial virus (RSV) vaccine, has met primary efficacy endpoints in phase 3 trial in older adults. Moderna. https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-mRNA-1345-an-Investigational-Respiratory-Syncytial-Virus-RSV-Vaccine-Has-Met-Primary-Efficacy-Endpoints-in-Phase-3-Trial-in-Older-Adults/default.aspx
Lee, I. T., Nachbagauer, R., Ensz, D., Schwartz, H., Carmona, L., Schaefers, K., Avanesov, A., Stadlbauer, D., Henry, C., Chen, R., Huang, W., Schrempp, D. R., Ananworanich, J., & Paris, R. (2023). Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mrna-based seasonal influenza vaccine (mrna-1010) in healthy adults: Interim analysis. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-39376-7
GSK. (2024). GSK's mRNA-based influenza vaccine demonstrates positive results in Phase II trial. Retrieved from https://www.gsk.com/en-gb/media/press-releases/gsk-s-mrna-based-influenza-vaccine-demonstrates-positive-results-in-phase-ii-trial/
Shaw, C. A., Essink, B., Harper, C., Mithani, R., Kapoor, A., Dhar, R., Wilson, L., Guo, R., Panozzo, C. A., Wilson, E., Simorellis, A. K., Reuter, C., Stoszek, S. K., Chen, G. L., Das, R., & Goswami, J. (2024). Safety and immunogenicity of an mrna-based RSV vaccine including a 12-month booster in a phase 1 clinical trial in healthy older adults. The Journal of Infectious Diseases, 230(3). https://doi.org/10.1093/infdis/jiae081
CDC. (2024, November 13). About estimated flu burden. Centers for Disease Control and Prevention. https://www.cdc.gov/flu-burden/php/about/index.html
Plotkin, S., Robinson, J. M., Cunningham, G., Iqbal, R., & Larsen, S. (2017). The complexity and cost of Vaccine Manufacturing – An Overview. Vaccine, 35(33), 4064–4071. https://doi.org/10.1016/j.vaccine.2017.06.003
Kgi-Admin. (2024, August 27). Risk adjusted net present value: What is the current valuation of Moderna’s mrna-1010. Pharmaceutical Technology. https://www.pharmaceutical-technology.com/data-insights/mrna-1010-moderna-net-present-value/
Uddin, M. N., & Roni, M. A. (2021). Challenges of storage and stability of mrna-based COVID-19 vaccines. Vaccines, 9(9), 1033. https://doi.org/10.3390/vaccines9091033
Worldometer. (2024, April 13). Coronavirus cases:. Worldometer. https://www.worldometers.info/coronavirus/
Downloads
Posted
License
Copyright (c) 2025 Kai-Li Hu, Adjoa Osei-Ntansah
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.